Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study-Reference-Cited by-同舟云学术

Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study

Published:2024-11-13 Issue:3 Volume:66 Page:529-534
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Sekeres Mikkael A.¹,Santini Valeria²,Díez-Campelo Maria³,Komrokji Rami S.⁴^ORCID,Fenaux Pierre⁵,Savona Michael R.⁶,Madanat Yazan F.⁷,Valcárcel-Ferreiras David⁸,Oliva Esther Natalie⁹,Regnault Antoine¹⁰,Creel Kristin¹⁰,Sengupta Nishan¹¹,Dougherty Souria¹¹,Shah Sheetal¹¹,Sun Libo¹¹,Wan Ying¹¹,Navada Shyamala¹¹,Zeidan Amer M.¹²,Platzbecker Uwe¹³

Affiliation:

1. Sylvester Comprehensive Cancer Center, University of Miami

2. Azienda Ospedaliero Universitaria Careggi, University of Florence

3. University Hospital of Salamanca

4. Moffitt Cancer Center

5. Hôpital Saint-Louis, Université de Paris 7

6. Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

7. Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center

8. Hospital Universitario Vall d’Hebron

9. Grande Ospedale Metropolitano BMM

10. Modus Outcomes, A Division of THREAD

11. Geron Corporation